読み込み中
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
前日終値
$2.69
+$0.03 · +1.13%
日中の時刻はETです。市場データは遅延する場合があります。
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
日中レンジ
現在 $2.69
52週レンジ
現在 $2.69
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
91
大幅な割安
センチメント
65
強気
リスク
71
高リスク
モメンタム
20
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
日中レンジ
現在 $2.69
52週レンジ
現在 $2.69
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.29億 USD | 9959.7万 USD | 8357万 USD | 7205万 USD | 6744.9万 USD |
| 売上原価 | 4623.4万 USD | 3801.1万 USD | 3279万 USD | 2925.3万 USD | 2595.9万 USD |
| 粗利益 | 8318.9万 USD | 6158.6万 USD | 5078万 USD | 4279.7万 USD | 4149万 USD |
| 研究開発 | 633万 USD | 601.6万 USD | 495.8万 USD | 482.6万 USD | 383.2万 USD |
| 販売・一般管理 | 6256.3万 USD | 4784.4万 USD | 5142.1万 USD | 5659.9万 USD | 6473.1万 USD |
| 営業費用 | 6889.3万 USD | 5386万 USD | 5637.9万 USD | 6142.5万 USD | 6856.3万 USD |
| 受取利息 | 212.7万 USD | 112.9万 USD | 66.1万 USD | 3000 USD | — |
| 支払利息 | — | — | — | — | 5.5万 USD |
| 減価償却費と償却費 | 145万 USD | 148.4万 USD | 170.5万 USD | 188.4万 USD | 162.6万 USD |
| 営業利益 | 1429.6万 USD | 772.6万 USD | −559.9万 USD | −1862.8万 USD | −2707.3万 USD |
| 純利益 | 1738.2万 USD | 855万 USD | −493.8万 USD | −1654万 USD | −2712.8万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$10.33
上昇余地（284.01%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2016年4月13日 | 1:3 | — | — |
発効済み 2016年4月13日
1:3
この株式へのエクスポージャーを報告している上場投資信託です。
Gabelli Love Our Planet & People ETFLOPP592.41万0.40%1470万 USD0.90%$35.84+0.52%
Vanguard Morningstar Total Stock Market ETFVTI460.37万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM405.03万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF206.03万0.00%954億 USD0.05%$235+0.80%
Vanguard Consumer Staples ETFVDC186.16万0.02%93億 USD0.09%$226.37+0.15%
iShares Russell 2000 Growth ETFIWO144.01万0.01%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO103.77万0.01%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA80.66万0.00%218.24億 USD0.03%$32.79+0.40%Gabelli Love Our Planet & People ETFLOPPVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Consumer Staples ETFVDCiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
